SpectraCure is developing a future system for treating internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. Today, available treatments for recurrent prostate cancer are controversial due to the severe side effects associated with several treatment options.
The company has its roots in research at Lund University, and the technology is based on long scientific research and clinical treatments with PDT, and photodynamic therapy at Lund University Hospital. Globally, a total of about one million PDT treatments for skin tumours are performed annually. SpectraCure has further developed this method for the treatment of internal solid tumours. The company’s interstitial PDT system with its proprietary IDOSE® software is a completely new medical technology system for treatment planning and dose delivery of laser light.
We are working to obtain market approval for the treatment system in both the North American and European markets. Our treatment system has the potential to be a beneficial alternative to available treatment methods for patients suffering from prostate cancer after previous radiation therapy.
We are currently conducting a clinical study on treatment of recurrent prostate cancer. Product approval for market launch will only occur after a successfully completed clinical study confirms the clinical benefit of the treatment in relation to its clinical risk in a larger number of patients.
Our strategy is to involve leading clinics in our clinical study and, through these reference clinics, establish clinical evidence, disseminate knowledge, and gain clinical acceptance of the treatment. The results from the study will be published and presented by influential urologists to gain impact.
Our intention is to engage with global industrial partners with the aim of gaining additional support and resources in our commercialisation process.
We have currently decided to focus on prostate cancer recurrence, but eventually aim to be able to treat primary prostate cancer and other cancer diagnoses, such as breast, pancreatic, head, and neck cancer. The vision is for our treatment to eventually be offered as an alternative to radiotherapy and surgery.
Prostate cancer affects around 700,000 people annually in the US and Europe. Of these, about 20% relapse after radiotherapy. The global prostate cancer market is growing and is estimated to be worth around $100 billion by 2026. The market is growing as more and more men are affected by prostate cancer, mainly due to an increase in life expectancy. The value of the market is also increasing as a result of more high cost, sophisticated treatments reaching the market.